Medical fiber and manufacturing method thereof

A manufacturing method and fiber technology, which is applied in the field of natural biological fiber and its manufacturing, can solve the problems of long time consumption, long time, and short fiber forming time, and achieve the goal of reducing spinning temperature, shortening production cycle, and eliminating the three wastes Effect

Inactive Publication Date: 2009-07-08
TIANJIN POLYTECHNIC UNIV
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This method takes too long, consumes too much energy, is very inefficient, and has the risk of being unsafe or unhygienic (secondary pollution)
Chinese patent literature (CN1270240A) discloses a hemostatic fiber with gelatin as the main component and comprising polyvinylpyrrolidone, water-soluble chitosan, and sodium alginate, which is spun by a centrifugal spinning process, and the resulting fiber is rapidly dried and formed, and The hemostatic fiber can be directly collected, packaged, and sterilized, but since polyvinylpyrrolidone is a synthetic substance, it is difficult for the human body to degrade it by itself, while chitosan and sodium alginate need special enzymes to degrade it, so the human body degrades it It takes a long time to absorb this kind of substance, and because the fiber-forming time is relatively short, and no cross-linking agent is used, the resulting fiber is easy to stick to hands and stick together, which is not conducive to practical use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Put 0.025g of N-hydroxysuccinimide (NHS) into 100g of distilled water and dissolve at 40°C; 149.975g of pharmaceutical grade gelatin with an average molecular weight of 200,000, 12.5g of pharmaceutical grade sericin with an average molecular weight of 40,000 Put into 900g distilled water with 87.5g average molecular weight of 4,000 pharmaceutical grade silk fibroin, and swell at room temperature for 180 minutes; be warming up to 80°C, stir and miscible for 100 minutes, and then filter the mixture; Stand at 60°C for defoaming for 6 hours, control the temperature of the feed liquid at 45°C, then mix the aqueous solution of the crosslinking agent and the mixture liquid, and send them to the centrifugal spinning machine for spinning through the metering pump, and the pump feed liquid The amount is 200g / min, the linear speed of the centrifugal disc is 6000 m / min, the spinning temperature in the spinning box is 220°C, and the feed liquid is rapidly spun into short fibers; afte...

Embodiment 2

[0033] Put 0.25g of 1-ethyl-3,3-dimethylaminopropyl-carbodiimide (EDC) into 150g of distilled water and dissolve at 40°C; 224.75g of pharmaceutical grade gelatin with an average molecular weight of 100,000, Put 2.5g of pharmaceutical-grade sericin with an average molecular weight of 1,000, and 22.5g of pharmaceutical-grade silk fibroin with an average molecular weight of 80 into 850g of distilled water, and swell at room temperature for 180 minutes; heat up to 70°C, stir and mix for 80 minutes, and then mix Filtration of the mixed material; the filtered mixed material liquid was left to defoam at 60°C for 6 hours, and the temperature of the material liquid was controlled at 35°C; then the aqueous solution of the crosslinking agent and the mixed material liquid were mixed evenly, and then entered into the centrifugal spinning through a metering pump. Silk machine, the pump supply is 40g / min, the centrifugal disc line speed is 3000m / min, the spinning temperature in the spinning b...

Embodiment 3

[0035] Put 0.075g of EDC into 100g of distilled water and dissolve at 40°C; 174.925g of pharmaceutical grade gelatin with an average molecular weight of 170,000, 10g of pharmaceutical grade sericin with an average molecular weight of 30,000, and 65g of pharmaceutical grade silk with a molecular weight of 3,000 Put it into 900g distilled water, swell at room temperature for 180 minutes; raise the temperature to 70°C, stir and mix for 90 minutes, then filter the mixture; let the filtered mixture stand at 60°C for 4 hours, and put the mixture The temperature is controlled at 40°C; after the aqueous solution of the crosslinking agent is uniformly mixed with the mixed material liquid, it enters the centrifugal spinning machine through a metering pump. Minutes, the linear speed of the centrifugal disc is adjusted to 4000 m / min, the spinning temperature is adjusted to 190°C, and the vacuum oven is dried at 80°C.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medical fibre and a manufacturing method thereof. The medical fibre has characteristics in composition by weight percent: 59.99-89.9% glutin with average molecular weight 10-20 ten thousands; 1-5% sericin with average molecular weight 1000-40000; 9-35% fibroin with average molecular weight 80-4000; 0.01-0.1% cross linker that is 1-ethide-3, 3-dimethyl aminopropyl-carbodiimide and/or N-hydroxide radical succimide. The method includes steps as follows: placing glutin, sericin and fibroin into distilled water according with weight percent composition, swelling 150-200 miniutes under 70-95 DEG. C for preparing spinning stock solution, reducing temperature to 35-45 DEG. C after filtering and deaeration, adding cross linker and mixing; using centrifugal spinning technique for spinning, drying and forming the obtained fibre rapidly, then placing into a vacuum baking oven for baking further, collecting, packaging, irradiating sterilizing by cobalt 60 gamma, and obtaining the medical fibre.

Description

technical field [0001] The invention relates to a fiber material manufacturing technology, in particular to a natural biological fiber suitable for medical use and a manufacturing method thereof. Background technique [0002] The use of natural biomaterials to manufacture medical fibers has been studied. For example, Chinese patent (application number is 92105622.2) document discloses a kind of with sodium alginate as raw material, with calcium chloride aqueous solution as coagulant, adopts the method for the absorbable hemostatic dressing of wet manufacturing; Chinese patent document (CN 85109219A) Disclosed is a technology for manufacturing medical hemostatic fibers by dry spinning process, the content of gelatin / polyvinyl alcohol (40--65 / 35-60) in the hemostatic fibers is 40-50%, and the rest is mainly soft water; China The patent document (CN 1157355A) discloses a "composition of hemostatic fiber and its spinning process by gas drawing method". The gelatin content in t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): D01F4/00D01D5/00A61L2/08
Inventor 齐鲁叶建忠邹建柱
Owner TIANJIN POLYTECHNIC UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap